Coherus Oncology, Inc.
CHRS
$1.60
$0.020.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -555.13% | -31,632.44% | -302.24% | -120.85% | 111.98% |
| Total Depreciation and Amortization | -44.88% | -42.61% | -22.08% | 10.72% | 39.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 115.57% | 152.21% | 169.66% | 178.81% | -217.60% |
| Change in Net Operating Assets | -68.14% | 625.02% | -90.71% | 301.07% | 251.78% |
| Cash from Operations | -349.52% | 29.73% | -9.15% | 100.33% | 88.31% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -138.01% | -132.04% | -105.69% | -96.88% | 67.33% |
| Cash from Investing | -138.01% | -132.04% | -105.56% | -96.95% | 59.24% |
| Total Debt Issued | -- | -100.00% | -100.38% | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 100.00% | -- | -- |
| Issuance of Common Stock | 238.47% | -92.05% | -98.34% | -98.73% | -96.79% |
| Repurchase of Common Stock | 89.22% | 90.08% | 90.40% | -28.63% | 30.97% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -99.93% | -99.99% | -100.04% | 6,647.48% | 3,632.79% |
| Cash from Financing | 104.18% | 99.98% | 99.89% | -382.12% | -368.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -849.17% | -847.26% | -189.21% | -172.87% | -41.80% |